Denosumab-associated hypocalcemia in a patient with chronic kidney disease and Paget's disease

[1]  S. Polyzos,et al.  Off-label uses of denosumab in metabolic bone diseases. , 2019, Bone.

[2]  M. Wilkowski,et al.  Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course , 2019, Case Reports in Nephrology and Dialysis.

[3]  Lakshmi R. Nair,et al.  Denosumab‐Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease , 2017, The American journal of the medical sciences.

[4]  S. Papapoulos,et al.  Paget's disease of bone. , 2001, Best practice & research. Clinical endocrinology & metabolism.

[5]  P. Choong,et al.  Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: A case report , 2017, Oncology letters.

[6]  A. Stewardson,et al.  Denosumab‐associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting , 2016, Pharmacoepidemiology and drug safety.

[7]  I. Reid,et al.  Treatment of Paget’s Disease of Bone with Denosumab: Case Report and Literature Review , 2016, Calcified Tissue International.

[8]  T. Ueda,et al.  Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  I. Reid,et al.  Paget's disease of bone: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[10]  M. Ghert,et al.  A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab. , 2014, The Journal of bone and joint surgery. American volume.

[11]  K. Skubitz.  Giant Cell Tumor of Bone: Current Treatment Options , 2014, Current Treatment Options in Oncology.

[12]  M. Xu,et al.  Denosumab and giant cell tumour of bone-a review and future management considerations. , 2013, Current oncology.

[13]  D. Wieczorek,et al.  Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. , 2013, The Journal of clinical endocrinology and metabolism.

[14]  K. Burns,et al.  Severe hypocalcemia following denosumab injection in a hemodialysis patient. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  N. Jørgensen,et al.  Paget's disease of the bone after treatment with Denosumab: a case report. , 2011, Bone.

[16]  G. Block,et al.  A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  von Tumorzellen.  Calcitriol , 2012, Reactions weekly.

[18]  S. Cummings,et al.  Effects of denosumab on fracture and bone mineral density by level of kidney function , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  J. Hashimoto,et al.  [Denosumab as the potent therapeutic agent against Paget's disease of bone]. , 2011, Clinical calcium.